Drug Profile
Vunakizumab - Jiangsu Hengrui Medicine
Alternative Names: SHR 1314Latest Information Update: 21 Jan 2024
Price :
$50
*
At a glance
- Originator Atridia; Jiangsu Hengrui Medicine Co.
- Developer Jiangsu Hengrui Medicine Co.; Suzhou Suncadia Biopharmaceuticals
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action IL17A protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Plaque psoriasis
- Phase II/III Ankylosing spondylitis
- Phase II Psoriatic arthritis
- No development reported Autoimmune disorders; Axial spondyloarthritis
Most Recent Events
- 26 Dec 2023 Suzhou Suncadia Biopharmaceuticals plans a phase I trial for Plaque Psoriasis (In volunteers) in China (SC, Injection) (NCT06182384)
- 24 Dec 2023 Suzhou Suncadia Biopharmaceuticals a phase I trial for Plaque psoriasis (In volunteers) in China (NCT06182384)
- 05 Dec 2023 Preregistration for Plaque psoriasis (SC), prior to December 2023 (Jiangsu HengRui Medicine pipeline, December 2023)